Cerenome, Inc.
NASDAQTotal Valuation
Cerenome, Inc. carries a market capitalization of 21.20M, placing it among publicly traded companies globally. Its enterprise value stands at -14.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 21.20M |
| Enterprise Value | -14.39M |
Share Statistics
Cerenome, Inc. currently has 6.86M shares outstanding.
| Shares Outstanding | 6.86M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Cerenome, Inc. maintains a current ratio of 2.27, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.06, indicating elevated leverage, while an interest coverage ratio of -6.01 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.27 |
| Quick Ratio | 2.07 |
| Debt / Equity | 6.06 |
| Debt / EBITDA | -0.04 |
| Interest Coverage | -6.01 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -74.63 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 3,119.69 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Cerenome, Inc.'s stock has declined approximately -23.95062% over the past 52 weeks. The 50-day moving average sits at 4.13, while the 200-day moving average is 7.78.
| Beta (5Y) | N/A |
| 52-Week Price Change | -23.95062% |
| 50-Day Moving Average | 4.13 |
| 200-Day Moving Average | 7.78 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -18.49M, while operating income came in at -18.88M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -18.88M |
| Pretax Income | -11.93M |
| Net Income | -11.93M |
| EBITDA | -18.49M |
| EBIT | -18.88M |
| Earnings Per Share (EPS) | -1.85 |
Balance Sheet
Cerenome, Inc. holds 15.11M in cash and equivalents against 725,000.00 in total debt, resulting in a net debt position of -2.35M. Total book value stands at 11.96M, with working capital of 10.07M providing operational flexibility.
| Cash & Cash Equivalents | 15.11M |
| Total Debt | 725,000.00 |
| Net Debt | -2.35M |
| Equity (Book Value) | 11.96M |
| Book Value Per Share | 1.74 |
| Working Capital | 10.07M |
Cash Flow
Cerenome, Inc. produced -20.84M in operating cash flow over the past twelve months. After subtracting -882,000.00 in capital expenditures, free cash flow totaled -21.72M - equivalent to -5.06 per share.
| Operating Cash Flow | -20.84M |
| Capital Expenditures | -882,000.00 |
| Free Cash Flow | -21.72M |
| FCF Per Share | -5.06 |
Scores
Cerenome, Inc. posts an Altman Z-Score of -40.64, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -40.64 |